Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer”

17 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 17 results

Testing effectiveness (Phase 2)Looking for participantsNCT07164170
What this trial is testing

Clinical Study of Combination Therapy With ABSK043 and Glecirasib

Who this might be right for
Non-Small Cell Lung Cancer
Abbisko Therapeutics Co, Ltd 86
Large-scale testing (Phase 3)Looking for participantsNCT07174908
What this trial is testing

IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

Who this might be right for
Non-Small Cell Lung Cancer
InxMed (Shanghai) Co., Ltd. 400
Testing effectiveness (Phase 2)Ended earlyNCT05492045
What this trial is testing

Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer

Who this might be right for
NSCLC
InventisBio Co., Ltd 22
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07827261
What this trial is testing

BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 36
Testing effectiveness (Phase 2)Looking for participantsNCT05631249
What this trial is testing

Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

Who this might be right for
KRAS P.G12CNon Small Cell Lung Cancer
Gustave Roussy, Cancer Campus, Grand Paris 40
Testing effectiveness (Phase 2)Looking for participantsNCT07198841
What this trial is testing

IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Who this might be right for
Lung Cancer (Non-Small Cell)
Guangdong Association of Clinical Trials 48
Large-scale testing (Phase 3)Looking for participantsNCT06119581
What this trial is testing

First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungNeoplasm Metastasis
Eli Lilly and Company 1,264
Testing effectiveness (Phase 2)Looking for participantsNCT07468071
What this trial is testing

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

Who this might be right for
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung CancerAdvanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07339839
What this trial is testing

Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC

Who this might be right for
NSCLC Stage IVKRAS G12C
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 42
Large-scale testing (Phase 3)Looking for participantsNCT06300177
What this trial is testing

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Who this might be right for
Non Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 522
Large-scale testing (Phase 3)Looking for participantsNCT06875310
What this trial is testing

Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Mirati Therapeutics Inc. 630
Large-scale testing (Phase 3)Study completedNCT04303780
What this trial is testing

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Who this might be right for
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Amgen 345
Large-scale testing (Phase 3)Not Yet RecruitingNCT07822542
What this trial is testing

A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Jiangsu Hansoh Pharmaceutical Co., Ltd. 448
Large-scale testing (Phase 3)Not Yet RecruitingNCT07833202
What this trial is testing

Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

Who this might be right for
NSCLC
Shanghai Jeyou Pharmaceutical Co., Ltd. 416
Early research (Phase 1)Looking for participantsNCT06946927
What this trial is testing

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
Jemincare 72
Testing effectiveness (Phase 2)Looking for participantsNCT06244771
What this trial is testing

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Who this might be right for
Advanced Solid Tumors With KRAS G12C MutationsSolid Tumor, AdultUnresectable Solid Tumor+5 more
Frontier Medicines Corporation 403
Testing effectiveness (Phase 2)Active Not RecruitingNCT05445843
What this trial is testing

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Who this might be right for
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Novartis Pharmaceuticals 95